ScreenerHero

LONALeonaBio Inc. Common Stock

NAS · US · Healthcare · Biotechnology · leonabio.com
7.685USD-1.85%Mkt Cap: 72.41M $P/E: —

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral scle…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap72.41M $
Enterprise Value22.06M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-105.61M $
Revenue/Share—
Last Price7.685 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.41
EV/Revenue—
P/S—
P/B1.47
EPS (TTM)-22.63
EPS (Forward)—
52W Range
3.53039% of range14.21
52W High14.21 USD
52W Low3.530 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-380.03%
ROA-114.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.73M $
CapEx (TTM)—
FCF Margin—
FCF Yield-32.80%
Net Debt-50.49M $
Net Debt/EBITDA0.94
Balance Sheet
Debt/Equity0.03
Current Ratio7.01
Quick Ratio6.53
Book Value/Sh5.249 USD
Cash/Share5.420 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateSep 18, 2025
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.33 USD
Upside (mean)+125.5%
Target Range15.00 USD – 20.00 USD
$15.00+125.5% to mean$20.00
# Analysts3
Ownership
Shares Out.9.42M
Float5.63M
Insiders4.49%
Institutions78.55%
Short Interest
Short Ratio1.1d
Short % Float0.55%
Short % Out.0.43%
Shares Short40.71K
Short (prev mo.)56.07K
Technical
SMA 508.130 (-5.5%)
SMA 2007.312 (+5.1%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)34.82K
Avg Vol (10d)90.22K
Technical Indicators
RSI (14)47.3
MACD-0.1007
MACD Signal-0.1761
MACD Hist.+0.0754
BB Upper8.130 USD
BB Middle7.535 USD
BB Lower6.940 USD
BB Width15.80%
ATR (14)0.5628 USD
Vol Ratio (20d)0.39x